In recent years, several novel therapeutic classes for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including antibody-drug conjugates, CAR T, and most recently, bispecific T-cell engaging antibodies have emerged. During this symposium, a panel of clinical experts will present the latest data on these therapeutic advances. They will also discuss the integration of these treatments in clinical practice while a patient with R/R DLBCL shares key aspects of their therapeutic journey.
Hybrid Friday Satellite Symposium on R/R DLBCL,
Preceding the 65th ASH Annual Meeting and Exposition
December 8, 2023 3:00 PM – 6:00 PM PT
*Register to Attend In-person or to Attend Virtually
Upon completion of this activity, participants should be better able to:
Director, Lymphoma Immunotherapy Program
Tisch Cancer Institute at Mount Sinai
Faculty, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
Mount Sinai Hospital
New York, NY
Assistant Attending, Lymphoma Service and Cellular Therapy Service
Memorial Sloan-Kettering Cancer Center
Assistant Professor, Medicine
Weill Cornell Medical College
New York, NY
Director, Indolent Lymphoma and Chronic Lymphocytic Leukemia
Associate Professor, Medicine
Hackensack Meridian School of Medicine
Hackensack, NJ
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
